The Peptide Patent Cliff: What 2027–2030 Means for the Industry
Between 2027 and 2030, patents on 14 peptide-based drugs representing $32 billion in combined 2025 revenue will expire. For an industry accustomed to exclusivity-driven pricing, this concentrated patent cliff represents both an existential threat and a transformative opportunity. How the peptide sector navigates this window will determine its structure for the next decade.
The Expiry Calendar
The patent cliff is not evenly distributed. The heaviest concentration falls in the GLP-1 space: Novo Nordisk’s semaglutide composition-of-matter patent expires in the US in March 2027 (with pediatric exclusivity extending to September 2027), and Eli Lilly’s tirzepatide follows in 2029. These two molecules alone account for $24 billion of the $32 billion at risk. Beyond diabetes and obesity, expiries include several somatostatin analogs (octreotide LAR, lanreotide), GnRH agonists (leuprolide, goserelin), and the calcitonin gene-related peptide (CGRP) antagonist class for migraine.
Notably, the peptide patent landscape is more complex than small molecules. Manufacturing process patents, formulation patents, and device patents (for injectables) often provide additional protection layers beyond the primary composition-of-matter patent. Semaglutide, for example, is protected by over 40 patents covering specific formulations, delivery devices, and manufacturing methods — some extending to 2034.
The Biosimilar Opportunity
Unlike small-molecule generics, peptide biosimilars require clinical testing to demonstrate similarity, creating a higher barrier to entry but also higher margins for successful entrants. The FDA has approved 12 peptide biosimilars to date, with an average of 3.2 years from filing to approval. Companies with established peptide manufacturing capabilities — particularly Biocon, Viatris (Mylan), and Sandoz — are best positioned to capture the biosimilar opportunity.
However, the scale of GLP-1 manufacturing presents a unique challenge. A biosimilar entrant would need to build or contract multi-ton peptide synthesis capacity — an investment exceeding $500 million for a single production line. This capital intensity may limit the number of viable biosimilar competitors to 3–4, preserving some pricing power for originators even after patent expiry.
Innovation Response
The smartest players are not waiting for the cliff. Novo Nordisk’s strategy of developing next-generation molecules (CagriSema, amycretin) that offer superior efficacy over semaglutide is designed to shift the prescribing base to on-patent products before biosimilar erosion begins. Eli Lilly’s orforglipron — an oral, non-peptide GLP-1 agonist — represents an even more radical hedge: a small molecule that bypasses peptide manufacturing constraints entirely.
The CGRP antagonist class offers a different model. As patents on injectable CGRP antibodies expire, the market is shifting toward oral small-molecule CGRP antagonists (gepants) that offer comparable efficacy with greater patient convenience. This pattern — peptides establishing a therapeutic concept, small molecules capturing the maintenance market — may recur across other indications.
What This Means for the Industry
The patent cliff will accelerate three structural shifts. First, consolidation: companies with mature, off-patent peptide portfolios will seek to acquire innovative pipelines. Second, manufacturing innovation: the $500 million biosimilar entry cost creates enormous incentive for cheaper synthesis technologies. Third, geographic expansion: biosimilar manufacturers in India, China, and Korea will use peptide biosimilars as a beachhead into regulated Western markets.
For the peptide industry, the 2027–2030 patent cliff is not a crisis — it is a stress test. Companies that invested early in next-generation molecules and manufacturing innovation will emerge stronger. Those that relied on patent thickets to protect aging franchises will face the consequences of commoditization. The peptide field is about to grow up — and the transition will not be gentle.